Voranigo_Benefit_Application
Defines coverage, prior authorization criteria, dosing/quantity limits, documentation requirements, and reauthorization rules for Voranigo (vorasidenib) for members 12 years and older with susceptible IDH1 or IDH2 mutated central nervous system tumors.
Reviewed and revised January 2026; current effective date listed as February 4, 2026.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.